Peter Thiel and Sam Altman lead Silicon Valley tycoons in aggressively investing in the longevity industry.

``` Billionaires are pouring vast sums of money into the longevity industry, once considered an academic fringe field, betting on scientific breakthroughs that could fundamentally change the human experience of life. According to analysis by The Wall Street Journal of PitchBook data, public company statements, and regulatory filings, over the past twenty-five years, the world’s top billionaires have invested more than $5 billion in the longevity sector; these include PayPal co-founder Peter Thiel, OpenAI CEO Sam Altman, tech investor Yuri Milner, and Marc Andreessen, among others. Correspondingly, over the past decade, the average amount raised by longevity companies has increased by more than 20%, reaching nearly $43 million this year. Among the most remarkable moves in this investment boom are Sam Altman’s $180 million infusion into Retro Biosciences, which focuses on cellular reprogramming, and Altos Labs’ record $3 billion fundraising at its inception. Despite high risks, such as the delisting and dissolution of Unity Biotechnology, investors remain undeterred in their pursuit of scientific frontiers. Through their financial bets, they are directing the flow of capital and scientific resources. Giants Converge, Investment Networks Emerge Silicon Valley’s investment ecosystem has fostered a highly interconnected longevity investment network. In this circle, personal connections and previous collaborations are key catalysts for new investments. Peter Thiel is one of the central figures in this network. According to The Wall Street Journal’s analysis, he has supported nearly a dozen longevity companies through his venture capital firm and nonprofit foundation, with these companies collectively raising over $70 billion. His "protégé," Sam Altman of OpenAI, made a major investment in Retro Biosciences, whose CEO Joe Betts-LaCroix previously worked at a biotech firm funded by Thiel’s firm. Additionally, Thiel’s fund has invested in NewLimit, co-founded by Coinbase CEO Brian Armstrong. NewLimit focuses on reversing cellular aging, and its investor roster reads like a “who’s who” of Silicon Valley’s billionaire set, including Palantir co-founder Joe Lonsdale, former Google CEO Eric Schmidt, and Sun Microsystems co-founder Vinod Khosla, among at least nine other billionaires or their funds. This pattern of mutual endorsement in investments is common; for example, Lonsdale's 8VC has invested in cellular regeneration startup Altos Labs, which is also backed by investor Yuri Milner. Spurred by these top billionaires, vast amounts of capital are flooding into the longevity arena at unprecedented speeds. Reports show that in the past twenty-five years, more than 200 related startups and nonprofit organizations have attracted nearly 1,000 investors, with a cumulative $12.5 billion in funding. Several companies have joined the “billion-dollar club”: - Altos Labs: Launched in 2022, focused on cellular regeneration technology, has raised $3 billion, the highest confirmed funding amount among its peers. - BioAge Labs: Develops drugs targeting age-related diseases, has raised $559 million, with investors including Khosla Ventures and Andreessen’s a16z fund. - Insilico Medicine: An AI drug discovery company, has raised over $500 million, aiming to treat a range of age-associated diseases. Investor enthusiasm has also pushed up fundraising levels in the sector. According to The Wall Street Journal’s calculations, over the past decade, average fundraising by longevity companies has increased by more than 20%, reaching nearly $43 million this year. However, high returns come with high risks. Unity Biotechnology, which raised $355 million since 2013, recently delisted from the Nasdaq and plans to dissolve, providing a warning of the sector’s investment risks. Huge Capital Flows into Three Main Areas Although there is no unified definition of a "longevity company," funds are flooding into three core segments of the longevity industry. First is reversing or altering aging. This is the most watched direction in Silicon Valley, with the central idea of using technologies like "reprogramming" to restore cells to a youthful state. Over 80 companies, including Altos Labs, Retro Biosciences, and Juvenescence, are working on this, having attracted about $5 billion in investments. Retro Biosciences claims its goal is to raise an additional $1 billion. Second is the treatment of age-related diseases. This approach views aging as the root cause of various chronic illnesses and aims to develop drugs to tackle these diseases. Nearly 60 biotech firms, including BioAge Labs, focus on this path, with cumulative funding approaching $5 billion. Third is immediate strategies for improving health and lifespan. For consumers eager to try anti-aging strategies right away, capital is also pouring into companies selling health trackers, supplements, and cosmetics; this sector has raised around $260 million. Personal Motivation Drives Investment Zeal Beyond the potential for massive returns, many investors’ bets are fueled by strong personal beliefs. Billionaire Naveen Jain said the death of his father from pancreatic cancer prompted him to found Viome Life Sciences and invest $30 million of his own money. Moderna CEO Stéphane Bancel, after trying a diet program developed by longevity scientist Valter Longo, led a $47 million investment in Longo’s company L-Nutra. Sun Microsystems co-founder Vinod Khosla is among the most prolific investors in longevity, once declaring: “At 70, a person should feel like they’re 40.” At the same time, a group of opinion leaders in the longevity sector has played a key role in attracting wealthy investors and public attention to the industry. Bestselling author Peter Attia, Harvard professor David Sinclair, and Bryan Johnson (who spends millions annually on self-experimentation) have used their influence to build the reputation and demand for the longevity industry. Entrepreneur Peter Diamandis, through his XPRIZE Foundation, set up a $100 million prize to spur the development of anti-aging technologies, further drawing in the attention and capital of global billionaires. Risk Warning and Disclaimer The market has risks, and investment must be cautious. This article does not constitute personal investment advice, nor does it take into account specific investment goals, financial situations, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable to their own circumstances. Investing based on this article is at your own risk. ```